4D Molecular Therapeutics (NASDAQ:FDMT) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 0 | 0 | 0 |
| Last 30D | 0 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $38.8, with a high estimate of $40.00 and a low estimate of $36.00. This current average represents a 10.6% decrease from the previous average price target of $43.40.
Understanding Analyst Ratings: A Comprehensive Breakdown
A clear picture of 4D Molecular Therapeutics's perception among financial...
Login or create a forever free account to read this news
Sign up/Log in
